| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
MADRID—Seeking to fulfill the data analysis demands of modern genomics research, genomics and proteomics IT solution provider Integromics SL and enterprise analytics software provider Tibco Software Inc. have combined their proprietary technologies to create a workflow-based, interactive software package for biomarker discovery.

According to the companies, the software, called Integromics Biomarker Discovery (IBD) for Tibco Spotfire, is designed to keep pace with advancing genomics research by giving researchers and scientists a more visual approach to data analysis that produces insights and relationships in genomics data with both accuracy and speed. Integromics and Tibco will co-market the software, which not only eases some of the data analysis challenges of genomics research, but also gives the companies a competitive edge, says Christian Marcazzo, senior director of Life Science Analytics for Tibco Spotfire.

"This solution helps researchers and scientists address one of the industry's long-standing challenges of creating knowledge from mass data by easily integrating multiple data sources and transforming data into an interactive decision-making asset," Marcazzo says. "Many vendors in this space tend to take the approach of building a new product from scratch to address the analysis of this kind of data. Our belief is that we have created a flexible data analysis platform, and combined with the expertise of a company like Integromics, we can move more quickly into the market to meet a specific research need."

IBD executes algorithms for statistical analysis of genomic data and facilitates user interaction through visualization screens and external biological database sources, walking the user through the workflow step-by-step. Using interactive visualizations, Spotfire enables users to ask and answer questions on demand. Together, the combined software enables researchers and scientists to quickly find and categorize complex patterns, examine the expression and annotation dimensions of their data and perform a variety of numerical analyses.

Having developed microarray analytics software for the last five years—including Real-Time StatMiner, which was developed in collaboration with Applied Biosystems and Novartis with a plug-in for the Spotfire platform—Integromics is confident the combined software will provide genomics researchers with accurate, up-to-date analytics as well as accelerate drug discovery, says Imad Yassin, the company's commercial director.

"This marriage of Integromics and Spotfire is covering a gap in the market with a balanced product that offers functionality, usability and the ability to ask questions," Yassin says. "This delivers powerful tools within one package without the researcher having to learn  programming or new, sophisticated algorithms." DDN

About the Author

Related Topics

Published In

Volume 4 - Issue 11 | November 2008

November 2008

November 2008 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A doctor wearing blue gloves and a white lab coat with a stethoscope around their neck holds a rendering of a digestive system on a glass pane with a swirled blue background.

Connecting the gut and liver to enhance drug development

Explore how a dual-organ microphysiological system connects human gut and liver tissue to bridge gaps in predicting how drugs behave in the body.
A syringe draws liquid from a glass vial, with several glass ampoules reflected on a glossy surface in the background

Turning up the heat: thermal analysis for biotherapeutics

Explore essential thermal stability techniques to ensure the safety, quality, and efficacy of biologic drugs.
A 3D-rendered image of a pink and white twisted RNA strand floating against a green, blurred cellular background.

Cutting the time and cost out of plasmid generation

Discover a hassle-free path to obtaining long, complex plasmid DNA.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue